The risk factors of clinical practice for bacteremia in community- acquired pneumococcal pneumonia Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016
Epidemiology, treatment and outcomes of nosocomial pneumonia due to Gram-negative bacteria Source: Eur Respir J 2007; 30: Suppl. 51, 408s Year: 2007
Ventilator-associated pneumonia: risk factors for antimicrobial-resistant causative pathogens Source: Eur Respir J 2006; 28: Suppl. 50, 785s Year: 2006
Long term survival and risk factors for gram-negative bacillary aetiology in patients with community-acquired pneumonia Source: Annual Congress 2009 - Aetiology and treatment of community-acquired pneumonia Year: 2009
Prevalence of atypical bacterial pathogens in hospitalized patients with community-acquired pneumonia Source: Annual Congress 2013 –Difficult and rare respiratory infections Year: 2013
Multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia Source: Annual Congress 2013 –Recent developments in pneumonia Year: 2013
Risk factors for drug-resistant pathogens in patients with hospital-acquired and ventilator-associated pneumonia Source: International Congress 2017 – Respiratory infections in critically ill and immuno-depressed patientes Year: 2017
Pulmonary disease as a risk factor for community-acquired pneumonia caused by multiple pathogens, including Streptococcus pneumoniae Source: Eur Respir J 2001; 18: Suppl. 33, 502s Year: 2001
Severe community-acquired pneumonia: assessment of microbial aetiology as mortality factor Source: Eur Respir J 2004; 24 : 779-785 Year: 2004
Community-acquired pneumonia in Europe: causative pathogens and resistance patterns Source: Eur Respir J 2002; 20: 20S-27S Year: 2002
Predicting bacteraemia or rapid identification of the causative pathogen in community acquired pneumonia: where should the priority lie? Source: Eur Respir J 2016; 48: 619-622 Year: 2016
Risk factors for infections with potentially resistant pathogens in patients in a pneumological intensive-care-unit Source: Eur Respir J 2002; 20: Suppl. 38, 476s Year: 2002
Incidence, characteristics and outcomes of patients with severe community acquired-MRSA pneumonia Source: Eur Respir J 2009; 34: 1148-1158 Year: 2009
The effect of macrolide-resistance on the outcome of patients hospitalized for streptococcus pneumoniae pneumonia Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management Year: 2015
The lung bacterial microbiome in community-acquired and nosocomial pneumonia Source: Eur Respir Monogr 2019; 83: 188-194 Year: 2019
Pneumonia caused by extensive drug-resistant Acinetobacter baumannii among hospitalized patients: genetic relationships, risk factors and mortality Source: International Congress 2017 – Respiratory infections in critically ill and immuno-depressed patientes Year: 2017
Is health care-associated pneumonia itself a predisposing factor for multi-drug resistant organisms? Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia Year: 2019
Epidemiology, antimicrobial resistance and clinical outcomes in nursing home associated pneumonia compared to community acquired pneumonia Source: Annual Congress 2013 –Antibiotics, resistance and vaccines Year: 2013
Diagnostic challenge in community-acquired pneumonia and hospital-acquired pneumonia: risk factors and diagnostic methods for methicillin resistant Staphylococcus aureus Source: Annual Congress 2006 - Methicillin resistant Staphylococcus aureus (MRSA): a real hospital-based pathogen? Year: 2006
Streptococcus pneumoniae resistance pattern and its clinical implicationsSource: Annual Congress 2006 - PG1 - Respiratory infections: pneumonia/antibiotic resistance and clinical outcome of lower respiratory tract infections Year: 2006